An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients
Phase 4
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: Peginterferon alfa-2a plus EntecavirDrug: Peginterferon alfa-2a plus LamivudineDrug: Peginterferon alfa-2a plus AdefovirDrug: Peginterferon alfa-2a plus Tenofovir
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 324
- Registration Number
- NCT02560649
Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer
Phase 4
Completed
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 294
- Registration Number
- NCT02549677
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL
Phase 2
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT02542111
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients
Phase 3
Terminated
- Conditions
- Breast Cancer
- Interventions
- Drug: Neoadjuvant endocrine therapyDrug: Neoadjuvant chemotherapy
- First Posted Date
- 2015-08-25
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT02532400
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients
Phase 4
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: nucleos(t)ide analgoue
- First Posted Date
- 2015-06-17
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 366
- Registration Number
- NCT02474316
- Locations
- 🇨🇳
The Third People's Hospital of Guilin, Guilin, China
🇨🇳Shanghai Public Health Clinical Center, Shanghai, China
🇨🇳Ruijin Hospital, Shanghai, China
The Effectiveness of Deep Brain Stimulation for Opioid Relapse Prevention
Phase 2
- Conditions
- Opiate Addiction
- Interventions
- Device: Suzhou Sceneray® DBS System
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2017-06-29
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT02440152
- Locations
- 🇨🇳
Shanghai RuiJin Hospital Psychitric Department, Shanghai, Shanghai, China
🇨🇳Shanghai Mental Health Center, Shanghai, Shanghai, China
China Refractory Obsessive-Compulsive Disorder Deep Brain Stimulation Study
Phase 2
Withdrawn
- Conditions
- Obsessive Compulsive Disorder
- Interventions
- Device: Sham Bilateral Nucleus Accumbens DBSDevice: Bilateral Nucleus Accumbens DBS (Suzhou Sceneray)
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Ruijin Hospital
- Registration Number
- NCT02398318
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
🇨🇳West China Hospital, Chengdu, Sichuan, China
🇨🇳Guangzhou psychiatric hospital, Guangzhou, Guangdong, China
Safety and Effectiveness of Capsulotomy in Refractory OCD
Phase 2
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Procedure: Anterior Capsulotomy
- First Posted Date
- 2015-03-02
- Last Posted Date
- 2015-04-28
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT02375152
- Locations
- 🇨🇳
Shanghai Ruijin Hospital, Shanghai, Shanghai, China
The Link Between the Clinical Resting Heart Rate and Sympathetic Overactivation
- Conditions
- Cardiovascular Disease
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2014-12-11
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT02315313
Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery
Phase 4
Completed
- Conditions
- Coronary Artery BypassAntiplatelet Agents
- Interventions
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT02201771
- Locations
- 🇨🇳
Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Nan Jing First Hospital, Nanjing, Jiangsu, China
🇨🇳Henan Provincial People's Hospital, Zhengzhou, Henan, China
© Copyright 2025. All Rights Reserved by MedPath